While retinal laser coagulation and the intravitreal injection (IVI) of corticosteroids still play essential roles in treating DME [5,6], intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents has transformed the standard of care for retinal diseases [7]. This evidence concerns the gene VEGFA and Abnormal retinal morphology.